




# Biomarker technologies for cardiovascular health

**Corporate Update Webinar**  
**6 Aug 2024**



# Cardiex Webinar Participants



**Craig R. Cooper**  
CEO



**Niall Cairns**  
Executive Chairman



**Catherine Liao**  
Chief Strategy Officer



**Dr. Mark Gorelick**  
Chief Product Officer



**Brian Schaechter**  
Senior Director of Sales –  
Pharmaceutical



**Rosemarie Diehl**  
Senior Director, Demand  
Generation



**Rod Hinchcliffe**  
Media & Capital Partners

# June 2024 Quarterly Highlights



 **Record annual company revenues – \$12.4m.**

- **Initial Pulse units arrived** in USA & Australia.
- Marketing and demand generation campaigns driving awareness and demand.
- New partnerships and pilot programs.
- **Initial Pulse production run increased to 8,000** (previously 3,000).
- **Pre-submission phase for OTC FDA-clearance for the Pulse.**
- **New patent awarded** by USPTO for wearable PPG sensor technology.
- Nearing completion of our wearable sensor validation study.
- FDA submission for wearable technology anticipated Q1 25.

# Financial Overview (Q4 ending 30 June 2024)




- Revenue and other income for **FY24 of \$12.4m** (FY23 - \$6.0m)
- Q4 operating cash outflows of \$2.8m, being a significant reduction to the Q3 normalized operating outflows of \$3.4m, due to:
  - Higher cash receipts of \$0.9m in Q4 vs \$0.7m in Q3, and
  - FY23 R&D tax incentive of \$0.7m.
- **Cash resources and reserves ~ \$6.5m**, comprising:
  - \$0.5m cash; and
  - \$6.0m being funded under the Funding Commitment Agreement with C2 Ventures.
- Cash resources are believed to be sufficient to fund the Company's growth initiatives, its operations, and to meet its business objectives.


# Financial Overview



## Revenue




## Revenue & Other Income






# Product Development

# CONNQ T Digital Product Suite



World-first Vascular Biometrics Monitor

CONNQ T PULSE



FDA CLEARED

April/2023



World-first Dual-Sensor Wearable Technology

Anticipated FDA clearance Q4 CY24

# CONNQQT Pulse Arrival



**FDA** | CLEARED

April/2023



*“It is a game-changer to be able to get regular measurements of key arterial health biomarkers in their home and work environments. I recommend that all my patients get a Pulse device even if they don’t have high blood pressure.”*

Dr. Joe Raffaele





# 2024



**JULY  
2024**

**130 Trial  
Production Units  
Landed in US.**  
Ready for internal  
testing.

**AUG  
2024**

**Sign off for Mass  
Production**  
following  
successful system  
and user end-to-  
end testing.

**App Store  
Submission**

**SEP  
2024**

**Start of Mass  
Production  
Phase**

**OCT  
2024**


**8k Mass  
Production  
Units Landed  
in USA**

**Mobile App &  
HCP Launch**

# Pulse QA & User Testing



- The Quality Assurance Team is conducting thorough system-level testing to assess the data flow from the Pulse device to both the mobile app and CONNEQT Cloud.
- The team is also evaluating the educational resources available in the CONNEQT app for their clarity and effectiveness.
- The goal is to ensure a seamless experience for the end users of the Pulse.
- The objective is to enhance user satisfaction and performance in real-world usage of the Pulse.



# 2024



MAR  
2024

JUL  
2024

AUG  
2024

SEPT  
2024

**Completion of HEARTsense Wearable Study** validating SphygmoCor® biomarker technology in wearables.

**Official publication of key wearable patent** by the United States Patent and Trademark Office (USPTO) (Patent #US12,029,5380).

**Publication of HEARTsense Wearable Study Results** in leading industry journal.

**Commencement of FDA submission.**




# Sales & Marketing

# Partner Programs



PHYSIOAGE®



Heartbeat

CONNEQT PULSE

Vitality starts with active monitoring of your vitals.

**Track what matters<sup>®</sup>** with CONNEQT Pulse.

[Join Waitlist](#)

FDA CLEARED

Powered By  
SphygmoCor<sup>®</sup>

## A revolution in health management.

With CONNEQT Pulse, you can finally **access advanced arterial health screening in the comfort of your home**. Track the vascular biomarkers utilized by all the USA News & World Reports "Top US Hospitals" and receive personal support from our network of cardiologists to monitor your vascular age & arterial health.

[Join Waitlist](#)

# Email Nurture



CONNQ.T.  
Health



## Understanding Arterial Stiffness

Hi Catherine,

Thanks again for joining our waitlist for the world's most advanced home arterial health monitor.

Arterial stiffness is a critical indicator of cardiovascular health that often goes unnoticed. As we age, our arteries can lose their elasticity, becoming stiffer and less able to accommodate blood flow. This condition can lead to increased blood pressure and a higher risk of heart disease and stroke, as well as many other health disorders.

*"Man is only as old as his arteries."*

Thomas Sydenham (1624–1689), English Hippocrates

By regularly monitoring arterial stiffness, you can gain critical insights into your cardiovascular health, empowering you to make informed decisions and take proactive steps in improving overall well-being and maximizing health span.

CONNQ.T.  
Health



## Assessing Arterial Stiffness at Home


Hi Catherine,

Continuing from our last newsletter on understanding arterial stiffness, we're thrilled to introduce [CONNQ.T. Pulse](#), a personal arterial health monitoring system developed by Cardiex, the company behind the pioneering [SphygmoCor® technology](#). Our technology is trusted by thousands of hospitals, clinicians, and researchers worldwide, setting the gold standard for assessing arterial health.

CONNQ.T. Pulse uses the same clinically validated SphygmoCor® technology to provide comprehensive insights into your arterial health that standard cuff blood pressure monitors cannot. This includes key health indicators such as arterial stiffness and [central blood pressure](#), all accessible from the comfort of your home.

*"New methods that assess arterial pressure and flow dynamics, beyond focus on conventional upper-arm blood pressure, are needed."*

CONNQ.T.  
Health



## Discover the Personal Health Benefits of the CONNEQT Pulse

Hi Catherine,

Imagine if you could gain deeper insights into your health and identify early signs of health concerns. [Early vascular aging](#) is one such insight, as it can affect the health of your heart, brain, kidneys, as well as your sexual health.

Deeper health insights also allow for more timely interventions that can prevent more severe health problems. We designed the [CONNQ.T. Pulse](#) to help you achieve this level of understanding and control over your health.

The CONNEQT Pulse is **the world's most advanced personal arterial health monitor** providing detailed information about the functionality of your arteries and the effort your heart exerts to deliver oxygenated blood to all major organs. By assessing your arterial health, the CONNEQT Pulse enables you to take proactive steps in improving overall well-being and maximizing health span.

*"The future of medicine lies in empowering"*

CONNQ.T.  
Health




Hi Catherine,

Advanced arterial health management offers enlightening insights into your well-being, helping you identify early signs of potential health concerns. These insights can significantly impact the health of your heart, brain, kidneys, and more, enabling timely interventions to prevent more severe issues.

Take me, for instance. I'm an energetic 58-year-old with a family history of heart disease and was diagnosed with hypertension at age 25. For the past 33 years, I've made lifestyle changes and complemented them with blood pressure-lowering medication to keep my heart health in check. Being able to track my arterial health has been a game-changer for me.

Measurements provided by traditional cuffs - blood pressure at the arm and one's heart rate.






# Pulse Waitlist Demand



# Digital Presence Amplification

1. Relaunch of Cardiex.com:
  - **67%** increase in user traffic
  - **184%** increase in page views
2. Increase in online ads, programmatic advertising, and search engine marketing
3. Sponsorship of leading industry websites (JAMA, JACC, Hypertension)
4. Conclusion of our inaugural Cardiex Arterial Research Initiative, which attracted research submissions from around the globe, and garnered over 20,000 votes worldwide in the final winner selection process.



# Industry Engagements and Activations



**WEBINAR** Hosted by: American Heart Association Center for Health Technology & Innovation In collaboration with: CARDIEX

## Heart Talks: Navigating Vascular Age for Heart Health

May 23, 2024

 <b>Catherine Liao</b> Moderator Chief Strategic Officer, Cardix	 <b>Dr. Purvi Parwani</b> MBBS MPH FACCC Associate Professor of Medicine Director, Echocardiography Lab Advanced Cardiovascular Imaging Loma Linda University Health	 <b>Dr. Michael V. McConnell</b> MD, MSEE Clinical Professor, Medicine - Cardiovascular Medicine Stanford, University	 <b>Dr. Sanjeev Bhavnani</b> MD, FACCC Senior Cardiologist - PI Digital Health & AI Clinical Trials Division of Cardiology Scripps Clinic
---	--	--	---



**Successful webinar collaboration with American Heart Association (AHA) on "Vascular Aging", moderated by our Chief Strategy Officer, Catherine Liao**

**Participated in three industry events** where we offered complimentary arterial assessments:

- American College of Sports Medicine (ACSM)
- North American Artery (NAA)
- Drug Information Association (DIA)

# Our Focus on Pharma and Service Providers


contacts in our network



**Brian Schaechter**

Senior Director of Sales –  
Pharmaceutical

# Current Clinical Trial Opportunities Across Disease States



# Devices for all Types and Phases of Clinical Trials



## Phase of Clinical Trials

- Phase I
- Phase IIA (Pilot studies designed to address optimal dosing and safety)
- Phase IIB (Provides data on efficacy)
- Phase III
- Phase IV

**\$5M**  
Current Pipeline

## Types of Clinical Trials

- Site-based
- Decentralized
- Hybrid



# Looking Ahead



## **Successful commercial launch of the Pulse**

- **Multiple** new product launch, distribution and sales partnerships.
- **Continuing** brand, education, and demand generation campaigns.
- **2 additional FDA clearances.**
  - Pulse OTC ("over the counter"); and
  - CONNEQT Band
- **Strong revenue growth** from our Clinical Trial Solutions group.
- **Accelerating revenue contributions** from new product releases (SaaS, subscription, lease revenues, product sales).
- **Consistent cadence of news and investor updates** (webinars, ASX, newswires, industry journals, conferences, seminars).



# Thank You